Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report
Artículo
Acceso abierto
Artículo
DOAJ
HER2-low breast cancer, defined as immunohistochemistry (IHC) 1+ or 2+ with negative in situ hybridization (ISH), has emerged as a clinically relevant therapeutic subgroup. We report the case of a 40-year-old woman with ...
LCC TENDOk5lb3BsYXNtcy4gVHVtb3JzLiBPbmNvbG9neS4gSW5jbHVkaW5nIGNhbmNlciBhbmQgY2FyY2lub2dlbnM~Idioma eng
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access